연구동향 분석
박사

Regulation of HIF1 and IL-8 using RNAi induces anti-tumor effects in hepatocellular carcinoma

최성훈 2015년

논문상세정보
인용/피인용
' Regulation of HIF1 and IL-8 using RNAi induces anti-tumor effects in hepatocellular carcinoma' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • angiogenesis
  • cell survival
  • hepatocellular carcinoma
  • hif-1α
  • hypoxia
  • il-8
  • tumor xenograft mouse model
  • tunel
  • 세포사
  • 아데노바이러스매개의 작은 헤어핀구조
  • 저산소
  • 저산소유도인자-1α와 β
  • 종양증식
  • 향종양 효과
  • 혈관 신생
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
454 0

0.0%

' Regulation of HIF1 and IL-8 using RNAi induces anti-tumor effects in hepatocellular carcinoma' 의 참고문헌

  • Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nature reviews Clinical oncology 2011, 8(5):292-301.
  • Yoshiji H, Kuriyama S, Yoshii J, Yamazaki M, Kikukawa M, Tsujinoue H, et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 1998; 28(6): 1489-96.
  • Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, Kang YA, et al. Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 2008; 15(9): 635-51.
  • Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 2000; 7(4): 725-9.
  • Wood SM, Gleadle JM, Pugh CW, Hankinson O, Ratcliffe PJ. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. The Journal of biological chemistry 1996, 271: 15117-23.
  • Welling TH, Fu S, Wan S, Zou W, Marrero JA. Elevated serum IL-8 is associated with the presence of hepatocellular carcinoma and independently predicts survival. Cancer investigation 2012, 30(10):689-97.
  • Weidemann A, Johnson R. Biology of HIF-1α. Cell death and Differentiation 2008; 15: 621-27.
  • Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14(21): 6735-41.
  • Wang Y, Li Y, Wang D, Li Y, Chang A, Chan WK. Suppression of the hypoxia inducible factor-1 function by redistributing the aryl hydrocarbon receptor nuclear translocator from nucleus to cytoplasm. Cancer letters 2012, 320: 111-21.
  • Wang L, Park H, Chhim S, Ding Y, Jiang W, Queen C, et al. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Molecular cancer therapeutics 2012, 11: 864-72.
  • Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(9):4304-08.
  • Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002,296:1635-36.
  • Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005; 65(4): 1294-305.
  • Tanaka H, Yamamoto M, Hashimoto N, Miyakoshi M, Tamakawa S, Yoshie M, et al. Hypoxia independent overexpression of hypoxia inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. Cancer Res 2006, 66:11263-70.
  • Tail SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol 2010, 11:621-32.
  • Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(9):4748-53.
  • Sparmann A, Bar-sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6(5): 447-58.
  • Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nature reviews Gastroenterology & hepatology 2009, 6(7):423-32.
  • Sogawa K, Nakano R, Kobayashi A, Kikuchi Y, Ohe N, Matsushita N, et al. Possible function of Ah receptor nuclear translocator (Arnt) homodimer in transcriptional regulation. Proceedings of the National Academy of Sciences of the United States of America 1995, 92: 1936-40.
  • Shimamura T, Saito S, Morita K, Kitamura T, Morimoto M, Kiba T, et al. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 2000; 15(6): 640-6.
  • Shi S, Yoon DY, Hodge-Bell K, Huerta-Yepez S, Hankinson O. Aryl hydrocarbon nuclear translocator (hypoxia inducible factor 1beta) activity is required more during early than late tumor growth. Molecular carcinogenesis 2010, 49: 157-65.
  • Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3(10): 721-32.
  • Schattenberg JM, Galle PR, Schuchmann M. Apoptosis in liver disease. Liver international : official journal of the International Association for the Study of the Liver 2006, 26(8):904-11.
  • Sampat KR, O'Neil B. Antiangiogenic therapies for advanced hepatocellular carcinoma. The oncologist 2013, 18(4):430-8.
  • Rust C, Gores GJ. Apoptosis and liver disease. The American journal of medicine 2000, 108(7):567-74.
  • Roessler S, Budhu A, Wang XW. Future of molecular profiling of human hepatocellular carcinoma. Future oncology 2007, 3: 429-39.
  • Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009; 61(9): 746-59.
  • Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9(6): 677-84.
  • Pollenz RS, Sattler CA, Poland A. The aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein show distinct subcellular localizations in Hepa 1c1c7 cells by immunofluorescence microscopy. Molecular pharmacology 1994, 45: 428-38.
  • Park SY, Han J, Kim JB, Yang MG, Kim YJ, Lim HJ, et al. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. Eur J Cancer 2014, 50(2):341-50.
  • Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007; 72 Suppl 1: 30-44.
  • Onuta G, Westerweel PE, Zandvoort A, van Riezen M, Rozing J, Hillebrands JL, et al. Angiogenic sprouting from the aortic vascular wall is impaired in the BB rat model of autoimmune diabetes. lMicrovascular Research. 2008;75(3):420-5.
  • Muntane J. Targeting cell death and survival receptors in hepatocellular carcinoma. Anti-cancer agents in medicinal chemistry 2011, 11(6):576-84.
  • Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005; 11(9): 992-7.
  • Martin D, Galisteo OR, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009; 284(10): 6038-42.
  • Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002; 5(4): 237-56.
  • Liu QY, Rubin MA, Omene C, Lederman S, Stein CA. Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clinical cancer research : an official journal of the American Association for Cancer Research 1998, 4(7):1803-11.
  • Kudo M. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. Digestive diseases 2011, 29(3):273-7.
  • Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K, et al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Annals of surgical oncology 2005, 12(10):800-7.
  • Kress S, Stein A, Maurer P, Weber B, Reichert J, Buchmann A, et al. Expression of hypoxia-inducible genes in tumor cells J Cancer Res Clin Oncol 1998;124: 315-320.
  • Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatocellular carcinoma. Hepato-gastroenterology 2003, 50(49):242-9.
  • Kietzmann K, Cornesse Y, Brechtel K, Modaressi S, Jungermann K. Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF-1alpha, HIF-2alpha and HIF-3alpha, in rat liver. Biochem J 2001,354:531-37.
  • Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Molecular pharmacology 2006, 70: 1469-80.
  • Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009, 115(21):4895-906.
  • Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001,292:468-72.
  • Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2(1): 38-47.
  • H pfl G, Wenger RH, Ziegler U, Stallmach T, Gardelle O, Achermann R, et al. Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res 2002; 62(10): 2962-70.
  • Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol 2011; 80(1): 40-53.
  • Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell,147:742-58.
  • Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World journal of gastroenterology : WJG 2009, 15(5):513-20.
  • Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver international : official journal of the International Association for the Study of the Liver 2007, 27(2):155-62.
  • El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998; 27(6): 1554-62.
  • Dong Z, Wang J. Hypoxia selection of death-resistant cells. A role for Bcl-X(L). The Journal of biological chemistry 2004, 279(10):9215-21.
  • Dittel BN, Merchant RM, Janeway CA, Jr.. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. Journal of immunology 1999, 162(11):6392-00.
  • Daniel NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004,116:205-19.
  • Choi SH, Shin HW, Park JY, Yoo JY, Kim do Y, Ro WS, et al. Effects of the knockdown of hypoxia inducible factor-1alpha expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. Korean J Hepatol 2010; 16(3): 280-7.
  • Choi SH, Kwon OJ, Park JY, Kim do Y, Ahn SH, Kim SU, et al. Inhibition of tumour angiogenesis and growth by small hairpin HIF-1α and IL-8 in hepatocellular carcinoma. Liver Int 2014, 34(4):632-42.
  • Choi SB, Park JB, Song TJ, Choi SY. Molecular mechanism of HIF-1-independent VEGF expression in a hepatocellular carcinoma cell line. Int J Mol Med 2011, 28(3):449-54.
  • Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M, Wenger RH. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1alpha. Journal of cell science 1999, 112 ( Pt 8): 1203-12.
  • Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. The Journal of biological chemistry 2009, 284(15):10004-12.
  • Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, et al. Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. Am J Pathol 2009; 175(1): 400-11.
  • Chavey C, M hlbauer M, Bossard C, Freund A, Durand S, Jorgensen C, et al. Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in breast cancer. Mol Pharmacol 2008; 74(5): 1359-66.
  • Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
  • Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008; 451(7181): 1008-12.
  • ?1. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41(5): 864-80.